Enjoy complimentary customisation on priority with our Enterprise License!
The predicted growth for the primary immunodeficiency therapeutics market from 2021 to 2026 is USD 3.13 billion at a progressing CAGR of 7.73%.
This primary immunodeficiency therapeutics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. The primary immunodeficiency therapeutics market report offers information on several market vendors, including ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd. among others.
This report further entails primary immunodeficiency therapeutics market segmentations, including:
Download the Free Report Sample to Unlock the Primary Immunodeficiency Therapeutics Market Size for the Forecast Period and Other Important Statistics
The increasing prevalence of immunodeficiency diseases is notably driving the primary immunodeficiency therapeutics market growth, although factors such as side effects of immunotherapy may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the primary immunodeficiency therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Primary Immunodeficiency Therapeutics Market Driver
Key Primary Immunodeficiency Therapeutics Market Trend
Key Primary Immunodeficiency Therapeutics Market Challenge
This primary immunodeficiency therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global primary immunodeficiency therapeutics market as a part of the pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the primary immunodeficiency therapeutics market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the primary immunodeficiency therapeutics market encompasses successful business strategies deployed by the key vendors. The primary immunodeficiency therapeutics market is fragmented and the vendors are deploying growth strategies such as partnership, agreement, collaboration, and joint ventures to compete in the market.
To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Our report provides extensive information on the value chain analysis for the primary immunodeficiency therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The primary immunodeficiency therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.
For more insights on the market share of various regions Request for a FREE sample now!
38% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the primary immunodeficiency therapeutics market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The increasing prevalence of immunodeficiency diseases and technological advancements in genetic and stem cell therapy will facilitate the primary immunodeficiency therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 outbreak in 2020 certainly had a negative impact on the primary immunodeficiency therapeutics market in North America. However, in 2021, the demand for these products rebounded, as manufacturing activities were reopened due to large-scale COVID-19 vaccination drives. These factors are expected to drive the growth of the regional primary immunodeficiency therapeutics market during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The primary immunodeficiency therapeutics market share growth by the antibody deficiency segment will be significant during the forecast period. The most common type of primary immunodeficiency in humans is antibody deficiency. It is a diverse category of diseases that cause the malfunction of one or more components of the immune system. Different parts of the immune system are affected by different types of primary immunodeficiency diseases. Antibody deficiency disorders, also known as humoral immunodeficiency diseases, primarily affect B cells. About half of the patients diagnosed with a primary immunodeficiency disease also have a primary antibody deficiency disorder. Such factors of antibody deficiency will drive the primary immunodeficiency therapeutics market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the primary immunodeficiency therapeutics market size and actionable market insights on the post-COVID-19 impact on each segment.
Primary Immunodeficiency Therapeutics Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.73% |
Market growth 2022-2026 |
$3.13 billion |
Market structure |
Fragmented |
YoY growth (%) |
5.3 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 38% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
ADMA Biologics Inc., Astellas Pharma Inc., Baxter International Inc., Bayer AG, Bio Products Laboratory Ltd., Biocon Ltd., Biotest AG, CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Lupin Ltd., Octapharma AG, Pfizer Inc., Sanquin, and Takeda Pharmaceutical Co. Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Disease Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.